Rick Simpson Oil (RSO) in Fulton County, Kentucky: The Complete Guide by OilWell Cannabis

Welcome to Fulton County — Where Tradition Meets Innovation

Fulton County sits in the far western corner of Kentucky, where the Mississippi River carves a natural border with Missouri and the rolling farmland of the Purchase Region stretches toward the horizon. This is a place where agriculture runs deep — soybeans, corn, and wheat fields paint the landscape, and the rhythms of rural life move with the seasons. It’s also a community that values hard work, family, and finding practical solutions to real problems.

For many in Fulton County, chronic pain, cancer support, sleep issues, and stress aren’t just abstract concerns. They’re daily realities. Whether it’s the physical toll of years spent farming, the emotional weight of caring for loved ones battling illness, or the quiet struggle of sleepless nights, people here know what it means to push through. And when conventional medicine doesn’t provide the relief they need, they look for alternatives — something that works with their bodies, not against them.

That’s where Rick Simpson Oil (RSO) comes in. Born from one man’s desperate search for healing, RSO has grown into a global movement — one that’s now reaching Fulton County in a way that’s safer, more precise, and more accessible than ever before. At OilWell Cannabis, we’ve taken the spirit of Rick Simpson’s original vision and evolved it into something new: a multi-cannabinoid, lab-tested, open-source RSO formula designed to meet the needs of modern patients.

This guide is for the people of Fulton County — the farmers, the caregivers, the veterans, the chronic pain sufferers, and the curious. It’s for anyone who’s ever wondered if there’s a better way to manage their health, and for those who are ready to explore cannabinoids with honesty, science, and real options.

Let’s start at the beginning.

The Rick Simpson Story: How One Man Changed Cannabis Forever

A Blue-Collar Beginning

Rick Simpson wasn’t a doctor, a scientist, or a medical researcher. He was a power engineer from Amherst, Nova Scotia — a working man who spent his life fixing things, solving problems, and taking care of his community. In 1997, his life changed when he fell from scaffolding at a hospital in Moncton, New Brunswick. The accident left him with persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine couldn’t resolve.

Simpson tried the medications his doctors prescribed, but they either didn’t help or made things worse. When he asked his physician about cannabis as an alternative, the request was refused. That moment — being told “no” by the very system that was supposed to help him — set Simpson on a path that would eventually redefine cannabis medicine.

The NIH Study That Started It All

Simpson’s interest in cannabis deepened after he learned about a 1974 study funded by the National Institutes of Health (NIH) and conducted at the Medical College of Virginia. The study, originally intended to demonstrate the harms of THC, found something unexpected: THC slowed or shrank tumors in mice. Though the findings were never replicated in controlled human cancer trials, they sparked Simpson’s curiosity and became a foundational reference point in his later advocacy.

The Basal Cell Carcinoma Moment

The turning point in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Instead of pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days.

Important context: Simpson’s experience is his personal testimony. There was no independent medical verification, no biopsy confirmation, and no peer-reviewed documentation of the outcome. While his story is historically significant as the catalyst for the RSO movement, it’s not medical evidence. In Fulton County, where many people have faced their own battles with cancer and chronic illness, it’s easy to see why Simpson’s story resonates. But it’s also important to understand the difference between personal experience and clinical proof — especially when making decisions about your health.

The Crusade Begins

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. He made the oil in large quantities and gave it away for free to cancer patients and others in his community, charging nothing. By his own account, he helped dozens of people with conditions ranging from cancer and chronic pain to diabetes, infections, glaucoma, arthritis, depression, and insomnia.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, featured testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Legal Battles and a Move to Europe

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and again in 2009, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he eventually left Canada and relocated to Europe, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Simpson’s Uncompromising Position

Throughout his public career, Simpson remained consistent in his beliefs: he maintained that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases. He also believed that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests.

Important context: Simpson’s conspiratorial framing is worth acknowledging, not because it’s true or false, but because it reflects a worldview shared by many in the early cannabis movement. In Fulton County, where trust in institutions can vary widely, it’s not uncommon to hear skepticism about pharmaceutical companies or government agencies. Simpson’s perspective resonates with that skepticism, but it’s also important to ground his claims in the actual evidence — which we’ll explore in detail later in this guide.

Traditional RSO: What It Was — and What It Wasn’t

The Traditional RSO Protocol: 60 Grams Over 90 Days

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. Here’s a detailed breakdown of the protocol as Simpson described it:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. By the end of this escalation period — roughly four to five weeks in — the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration Methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days.
• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period.

Post-Protocol Maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Here are the key points to consider:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks, including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the scientific literature.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What Is Traditional Rick Simpson Oil?

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. Here’s what traditional RSO was — and what it wasn’t:

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is difficult to verify without lab testing — leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. the Evidence: What the Science Actually Says

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

But what does the evidence actually say? Let’s evaluate Simpson’s claims against the current scientific literature.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• The National Center for Complementary and Integrative Health (NCCIH) explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

The Legacy of Rick Simpson: How RSO Evolved

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial — he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this guide.

Traditional RSO vs. Modern Formulated RSO: What’s the Difference?

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

1. Multi-Cannabinoid Approach

Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

2. Terpene Preservation and Addition

Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

3. THCa as a Separate Ingredient

Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

4. Reduced Delta-9 THC Dominance

Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Product Format Innovation

Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety: Why Modern Extraction Matters

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging — which is very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

The Decarboxylation Question: Patient-Controlled Potency

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius — was sufficient to convert essentially all THCa in the extract into delta-9 THC.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1: Raw, No Heat

All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2: Fully Activated, Home Decarboxylation

Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase.

Option 3: Vape, Auto-Decarboxylation

The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Terpenes: Why They Matter in Modern RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile, and the entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically.

Evidence Standards: Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense.

This guide takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

Simpson’s Protocol vs. Modern Dosing: Why They’re Not the Same

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Here are the key differences:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Meet OilWell Cannabis: The Company Bringing Modern RSO to Fulton County

From McAllen to Montrose: Colin Valencia’s Story

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story begins in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts: vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare. Reynosa, on the other side of the border, is an industrial hub plagued by violence and cartel activity.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin didn’t fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

Bentley’s Story: The Dog Who Started It All

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin wasn’t ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD — through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This wasn’t placebo effect — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey: From PTSD to Peace Gummies

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that is notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD.

This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

ABC13: Houston’s Trusted Voice on Cannabis

Between 2019 and 2023, ABC13 Houston — the ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

Here’s what the media record reveals:

• September 15, 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
• March 22, 2021: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
• May 24, 2021: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”* (This quote, delivered on live television, became one of Colin’s most iconic media moments.)
• August 20, 2021: OilWell gave away 1,000 caviar pre-rolls (valued at approximately $35,000) to encourage COVID-19 vaccination in partnership with the city of Houston.
• October 19, 2021: When Delta-8 was banned overnight, Colin proactively removed all products from his shelves before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics.
• October 7, 2022: Colin revealed that he has a personal marijuana conviction history, transforming the entire media narrative.
• April 21, 2023: “Right now is actually a pretty — like Renaissance — pretty important time that should be enjoyed now.”

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry.

The OilWell RSO Philosophy: Four Core Principles

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility Over Gatekeeping

No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-Source Formulas

OilWell publishes their complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section in this guide represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance: How OilWell’s RSO Stays Legal

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas: Why OilWell Publishes Everything

OilWell publishes their complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents including this guide. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone cannot afford OilWell’s products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this guide are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: they sell a professionally manufactured, lab-tested, standardized product for those who want it, and they publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy didn’t start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets — The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The Decarboxylation Choice: Patient-Controlled Potency in Action

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1: Raw, No Heat

All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2: Fully Activated, Home Decarboxylation

Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase.

Option 3: Vape, Auto-Decarboxylation

The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production: Safety You Can Trust

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The OilWell Product Portfolio: More Than Just RSO

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach

OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies

Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom Creations

OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats: Sublingual Oil and Vape Cartridge

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison: OilWell RSO vs. Alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market.

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery in Fulton County, nationwide and international shipping
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. Traditional Illegal RSO

Dimension	Traditional RSO	OilWell RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Condition-Specific Usage Context for Fulton County Residents

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this guide and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Accessibility: How Fulton County Residents Can Get OilWell RSO

OilWell operates the only same-day RSO delivery system in Houston, but the company also ships nationwide and internationally — including to Fulton County, Kentucky.

Nationwide Shipping to Fulton County

• Shipping options: USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging: No cannabis branding visible on the exterior
• Tracking: Provided for all orders
• Temperature-stable packaging: Ensures product integrity during transit
• Signature-required option: Available for added security

International Shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• Documentation: All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Shipping costs: Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• Legal responsibility: The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

Why This Matters for Fulton County

Rick Simpson couldn’t ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Fulton County, a chronic pain sufferer in Hickman, or a veteran in Fulton can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally — completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

The Science Behind OilWell’s RSO: What the Evidence Actually Says

Every cannabinoid and terpene in OilWell’s formula has its own evidence profile. Here’s what the science actually says about each one — and how it applies to Fulton County residents considering RSO for their health needs.

Cannabinoids

CBD (Cannabidiol)

• Evidence profile: Strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.
• What is best supported: Purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified.
• Pain research: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Sleep research: A 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments.
• Safety and interaction concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings.
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this formula, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing.

CBG (Cannabigerol)

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established.
• Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions.
• Caution: One of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid.

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.
• Public-health literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.
• Manufacturing context: The recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.
• Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid)

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC.

Delta-9 THC

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden.
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage.
• Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk.
• Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.
• Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products.
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this guide.

CBN (Cannabinol)

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What it is often marketed for: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Best direct review for the sleep claim: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Broader sleep literature: The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.
• Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene)

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and therapeutic interest: The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What the older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature.
• Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans.

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence.
• Research summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.
• Bottom line: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene (β-Caryophyllene)

• Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.
• Bottom line: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it.

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story.
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.
• Bottom line: Linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene

• Evidence profile: Translationally interesting, but still early.
• Scoping-review findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.
• Bottom line: Humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled.

Terpinolene

• Evidence profile: One of the least clinically characterized terpenes in this guide.
• Systematic-review findings: The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.
• Bottom line: Terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically.

Research Limits and Interpretation: What You Need to Know

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for Fulton County Residents

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

The OilWell Difference: Why Fulton County Residents Choose Us

When you’re considering RSO for your health, you deserve more than just a product — you deserve honesty, precision, and real options. Here’s what sets OilWell apart for Fulton County residents:

1. Multi-Cannabinoid Synergy

Traditional RSO was THC-only. OilWell’s formula includes seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity. This isn’t just marketing; it’s born from a decade of real-world formulation testing on a patient Colin loved more than anything.

2. Terpene Preservation

Traditional RSO destroyed terpenes through solvent and heat. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level. The terpenes aren’t just for flavor; they’re part of the experience and potentially part of the effect.

3. Patient-Controlled Potency

Traditional RSO was always fully psychoactive. OilWell’s formula includes THCa at 1,500 mg as a distinct ingredient, giving you the choice: use it raw for non-psychoactive benefits or heat it to activate full psychoactive potency. That’s control you won’t find in any other RSO product.

4. Reduced Delta-9 THC Dominance

Traditional RSO was 60 to 90 percent delta-9 THC. OilWell’s formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD, CBG, CBN, and CBC. This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Two Product Formats

Simpson envisioned only one format: an oral oil. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation. Whether you need fast relief (vape) or sustained support (sublingual), you have options.

6. Solvent-Free Production

Traditional RSO used naphtha or isopropyl alcohol — neither of which is food-grade. OilWell’s RSO is a formulated blend of individual cannabinoid distillates and isolates combined in a controlled production environment. No solvents. No residual risk. Just clean, lab-tested product.

7. Open-Source Formulas

OilWell publishes their complete formulas publicly. If you can’t afford the product, you can see exactly what’s in it, source the ingredients, and make your own version. Simpson gave his oil away for free; OilWell sells a professional product and gives away the recipe.

8. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section in this guide represents OilWell’s commitment to honest education. We don’t make claims that outrun the science. We don’t hype. We don’t sell snake oil. We tell you what the evidence actually says — and what it doesn’t.

9. Same-Day Delivery in Fulton County

OilWell doesn’t just ship to Fulton County — we deliver. Whether you’re in Hickman, Fulton, or anywhere in between, you can get OilWell RSO delivered to your door. No medical card required. No waiting for the mail. Just real, legal, lab-tested RSO when you need it.

10. Made in Houston, Trusted in Fulton County

OilWell is based in Houston, but our mission extends to Fulton County and beyond. We’re not a faceless online brand. We’re a real company with a real story — one that started with a man saving his dog and grew into a commitment to help people like you find real relief.

Final Thoughts: RSO in Fulton County — What’s Next?

Rick Simpson’s story began with one man’s search for healing. It grew into a global movement that changed how the world thinks about cannabis. And now, in Fulton County, Kentucky, that movement has evolved into something new: a multi-cannabinoid, lab-tested, open-source RSO formula designed for modern patients.

For the farmers in Fulton County who work long hours and need relief that doesn’t leave them impaired. For the caregivers who are exhausted from sleepless nights and need a natural option that works with their bodies. For the veterans who carry invisible wounds and need something that helps them find peace. For the cancer patients who are fighting for their lives and need every tool at their disposal. For the curious who are just starting to explore cannabinoids and need honest education.

This guide is for you.

At OilWell Cannabis, we believe in the power of cannabinoids — not because we think they’re a cure-all, but because we’ve seen what they can do. We’ve seen a paralyzed dog get up and walk. We’ve seen a man break free from benzodiazepine addiction. We’ve seen real people find real relief when nothing else worked.

But we also believe in honesty. We don’t make claims that outrun the science. We don’t hype. We don’t sell snake oil. We tell you what the evidence actually says — and what it doesn’t.

If you’re ready to explore RSO in Fulton County, we’re here to help. Whether you choose to purchase our products or make your own using our open-source formulas, we want you to have the best possible version of the information so you can give it a fair shot and decide for yourself whether it’s right or wrong for you.

Because at the end of the day, that’s what Rick Simpson’s vision was really about: giving people the tools they need to take control of their own health.

Welcome to the next chapter of RSO in Fulton County. We’re glad you’re here.